Financial Results

News & Events

Shareholders Meeting of May 28, 2020 – Availability of the preparatory documents and methods for participating and voting at the meeting

May 6, 2020

Daix (France), May 6, 2020 – Given the COVID-19 situation, and in accordance with the provisions of Order no. 2020-321 of March 25, 2020 adapting the form of meeting and decision-making rules for shareholders’ meetings and governing bodies of legal entities during the pandemic, Inventiva informs its shareholders and the entire financial community that its Combined (Ordinary and Extraordinary) Shareholders Meeting will be a closed meeting, with no shareholders physically present, at 2pm on May 28, 2020 at the Company’s registered office.

Terms of disposal of the preparatory documents

Documents for the Shareholders Meeting will be sent out by email. They can also be obtained upon request from the Company or downloaded from the “Investors/Shareholders Meeting” section of its website at

Participation modalities

Shareholders will be able to participate at the General Meeting by logging in to a webcast using one of the following two options:

  • Option #1 – Webcast:
  • Option #2 – Conference call:


France: +33 (0) 1 70 70 82 21
Belgium: +32 (0) 2 400 3439
Germany: +49 (0) 69 2443 7403
Netherlands: +31 (0) 20 715 7566
Switzerland: +41 (0) 44 580 6084
United Kingdom: +44 (0) 203 009 5709
United States: +1 646-787-1226

Access code: 7696007

A replay of the Shareholders’ Meeting will be available, approximately 2 hours after the event, at:

Voting modalities and written questions submission

Shareholders are invited to exercise their voting rights prior to the Shareholders Meeting, either by using the internet-based Votaccess secure platform or by sending in their form-based voting instructions by mail, or by appointing a representative. The arrangements for appointing third parties as representatives are those laid down in Article 6 of Decree no. 2020-418 of April 10, 2020.

Since no shareholders will be present in person at the meeting, it will not be possible to ask questions orally during the Shareholders Meeting. However, in order to encourage dialog, shareholders will have the opportunity to send their written questions to the Board of Directors no later than four business days ahead of the Shareholders Meeting, that is by Friday, May 22, 2020. They must be sent to the Company’s registered office by registered letter with return receipt requested. The questions must be accompanied by a certificate proving ownership of shares in the Company’s registered share accounts or in the bearer share accounts administered by third-party intermediaries, as listed in Article L. 211-3 of the French Commercial Code.

The detailed modalities for voting and submitting written questions prior to the Shareholders Meeting will be laid down in the notice of the Shareholders Meeting, which will be published in the French Bulletin of Legal Announcements (BALO) and in the “Investors/Shareholders Meeting” section of the Company’s website at


Frédéric Cren

Chief Executive Officer
+33 3 80 44 75 00


Aude Hillion/ Yannick Tetzlaff
Media relations
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.